Table 1 Characteristics of studies
Studies | Country | n | Design | Type of surgery | ASA | NMBRs (Intervention/comparator) | Age (years)* | Male (%)* | Outcome(s) assessed | Tool(s) used |
|---|---|---|---|---|---|---|---|---|---|---|
Piskin [26] | Turkey | 87 | Double-blinded RCT | Noncardiac Surgery | I-II | Neostigmine/Sugammadex | 37/32 | 51/71 | POCD | MMSE\MoCA |
Batistaki [25] | Greece | 160 | Double-blinded RCT | Noncardiac Surgery | I-III | Neostigmine/Sugammadex | 61/62 | 46/36 | POCD | MMSE |
Claroni [26] | Italy | 109 | Double-blinded RCT | Robotic-Assisted Radical Cystectomy | I-III | Neostigmine/Sugammadex | 60/63 | 73/78 | POCD | MMSE |
Kim [27] | Korea | 84 | Double-blinded RCT | Pars PlanaVitrectomy | I-III | Neostigmine/Sugammadex | 63/64 | 41/35 | POCD | PQRS |
Boggett [28] | Australia | 350 | Single-blinded RCT | laparoscopic surgery | I-III | Neostigmine/Sugammadex | 55/55 | 42/55 | POCD | PQRS |
Zhu [29] | China | 61 | Double-blinded RCT | Radical section of gastrointestinal tumors | I-III | Neostigmine/Placebo | 73/73 | 53/52 | POCD | MMSE |
Zhu [29] | China | 59 | Double-blinded RCT | Radical section of gastrointestinal tumors | I-III | Neostigmine/Placebo | 74/73 | 53/52 | POCD | MMSE |
Liu [30] | China | 401 | Double-blinded RCT | colon carcinoma surgery | I-III | Neostigmine/Placebo | 64/63 | 54/55 | POD | CAM |
Sabuncu [32] | Turkey | 84 | Open-label RCT | Bariatric surgery | I-III | Neostigmine/Sugammadex | > 18 | NR | POCD | MMSE |
Cao [31] | China | 64 | Double-blinded RCT | Noncardiac Surgery | I-III | Neostigmine/Placebo | 68/67 | 47/43 | POCD | MMSE |
Cao [31] | China | 66 | Double-blinded RCT | Noncardiac Surgery | I-III | Neostigmine/Placebo | 68/67 | 44/43 | POCD | MMSE |
Cao [31] | China | 66 | Double-blinded RCT | Noncardiac Surgery | I-III | Neostigmine/Placebo | 68/67 | 30/43 | POCD | MMSE |
Deng [33] | China | 114 | Double-blinded RCT | Noncardiac Surgery | I-III | Neostigmine/Placebo | 71/71 | 64/47 | POCD | MMSE\MoCA |